Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 11 years, with Q2 2025 value amounting to -$1.1 million.

  • Lifecore Biomedical, Inc. \De\'s Other Operating Expenses rose 5454.17% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was $409000.0, marking a year-over-year decrease of 9896.46%. This contributed to the annual value of $409000.0 for FY2025, which is 9896.46% down from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Other Operating Expenses of -$1.1 million as of Q2 2025, which was up 5454.17% from -$600000.0 recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Other Operating Expenses registered a high of $21.0 million during Q1 2024, and its lowest value of -$2.4 million during Q2 2024.
  • Its 4-year average for Other Operating Expenses is $4.7 million, with a median of $900000.0 in 2024.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Other Operating Expenses skyrocketed by 35000.0% in 2024, and later crashed by 10285.71% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Other Operating Expenses (Quarter) stood at $2.1 million in 2022, then soared by 881.97% to $20.7 million in 2023, then plummeted by 94.2% to $1.2 million in 2024, then plummeted by 190.92% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q2 2025, -$600000.0 for Q1 2025, and $1.2 million during Q4 2024.